No­var­tis stacks more pos­i­tive PhI­II da­ta on Cosen­tyx fran­chise — eye­ing ap­proval in non-ra­di­ograph­ic ax­i­al spondy­loarthri­tis

Days ago No­var­tis post­ed a brief note on pos­i­tive 16-week da­ta about Cosen­tyx’s ef­fects on non-ra­di­ograph­ic ax­i­al spondy­loarthri­tis, open­ing the door to an EMA sub­mis­sion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER